A number of pharmacological compounds that stimulate the activity of PPARδ, AMPK and SIRT1 have proven to be efficacious at relieving several DMD symptoms in animal models but there are several hurdles to overcome for their clinical development in DMD patients. Here, SIRT1 is linked to Duchenne muscular dystrophy.